Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
QuidelOrtho ( (QDEL) ) has provided an update.
On January 30, 2026, QuidelOrtho Corporation announced that board member Matthew W. Strobeck has decided not to stand for re-election at the company’s 2026 annual stockholders meeting due to other professional commitments. He will remain on the board until the annual meeting, after which the size of the board will be reduced from eleven to ten directors, with the company emphasizing that his departure is unrelated to any dispute or disagreement over its operations, policies, or practices and publicly expressing gratitude for his eight years of service.
The most recent analyst rating on (QDEL) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on QuidelOrtho stock, see the QDEL Stock Forecast page.
Spark’s Take on QDEL Stock
According to Spark, TipRanks’ AI Analyst, QDEL is a Neutral.
QuidelOrtho’s overall stock score reflects significant financial challenges, with declining revenue and profitability being the most critical factors. While technical indicators and corporate events show some positive signs, the negative valuation metrics and financial instability weigh heavily on the stock’s attractiveness.
To see Spark’s full report on QDEL stock, click here.
More about QuidelOrtho
QuidelOrtho Corporation is a diagnostics company that develops and markets in vitro diagnostic products and solutions used by healthcare providers and laboratories to detect and monitor a range of diseases and conditions, serving hospital, clinical, and other testing markets worldwide.
Average Trading Volume: 1,196,669
Technical Sentiment Signal: Sell
Current Market Cap: $1.99B
Find detailed analytics on QDEL stock on TipRanks’ Stock Analysis page.